Tina Moore
speaker
1,621 appearances
16 recordings
2 series
first heard Jan 2025
last heard May 2025
Tina Moore’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
But that said, those boundaries, and once I put those in, things got a lot better, a lot better. And I think it's something a lot of women in particular struggle with.
Yeah. Absolutely. I'm with you so much. We're taught to be accommodating. And there is a time and a place to be accommodating. And then at a certain point, it's just a no. And as I get older, I don't need to be as accommodating. I'm not trying to go along to get along anymore. And I'm not trying to be everybody's friend anymore. And I don't really care. And I'm a very, very...
huge hearted, generous human being. And at the same time, some people will say, you're such a bitch. And I'm like, yeah, I am. Like push me to that. And I'm very good at that too.
I love it. This has been so good and actually so helpful. It's very reassuring to hear you share so many similar experiences and feelings because it's nice to know we're not alone. And that's why I wanted to have you on. And that's why I've been so transparent throughout this episode with my audiences so that women understand that they're not alone either. These are just our quirks. They're
As long as we stay as healthy as possible and we take as good a care of ourselves as we can, I think they can be very powerful gifts and not so much a curse. But they can be a curse when things go sideways. And so knowing how to deal with that, and I think just step one is acknowledging there's a problem, or I shouldn't say a problem, but a difference, right? There's just something there.
And there's wonderful ways to navigate that. Yeah, absolutely. Absolutely. Yeah, well, where can everybody find you, Adele? Because your information has been so helpful.
I love it. And what's the website?
Okay. I'll make sure that the links are in the show notes for everybody so they can come find you and come follow you and learn from you. It's been such a treat to have you on today. Thanks so much for coming on. Yeah. Thanks for coming on the Dr. Tina show. Thanks for listening to The Dr. Tina Show. This is a Wellness Loud production produced by Drake Peterson and mixed by Mike Fry.
Theme song is by John the Guilt. You can watch the full video version of this podcast inside the Spotify app or on YouTube. As always, you can email the podcast at podcast at drtina.com. That's D-R-T-Y-N-A. And if you like this episode, please rate, review and subscribe on your favorite podcast app. You can also find all of my offerings on my website at drtina.com.
For more shows by my team, go to wellnessloud.com. See you next time and thanks for listening. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is intended not to be a substitute for professional medical advice, diagnosis, or treatment.
Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions.
The Dr. Tyna Show · GLP1s and Dementia: What the Latest Science Shows | Quick + Dirty · 1 May 2025
podcast
You are tuned into The Dr. Tina Show with Dr. Tina Moore. For more, visit drtina.com. On this episode of The Dr. Tina Show, I'm going to be sharing this study with you that showed a jaw-dropping 45% reduction in dementia risk. Not from some new Alzheimer's drug, not from some fancy intervention, but from good old GLP-1s. And I'm so excited to share the data with you. So let's jump in.
All right, so this was a very interesting study. They basically, it was done by two undergrad students, so that right there is very cool. They looked at 26 randomized control clinical trials, over 164,000 participants. And this study included patients with type 2 diabetes and cardiovascular risk factors and or actually.
And they looked at different types of blood sugar-lowering drugs like metformin, GLP-1s, SGLT-2s, SGLT-2 inhibitors, I'm sorry. And they compared them all and then they sorted out what cardiovascular benefits were happening and dementia risk. So the mean age participant was about 65 years old, 64.4 years, I guess 64 years old. 35% were women and the average duration follow-up was 31.4 months.
I will say that's a limitation of the study. They didn't follow up with them very long. And as we know, dementia takes decades to... So there's that. But overall, what they found, the key findings were that the cardioprotective glucose lowering therapies did not significantly reduce the risk of dementia or cognitive impairment overall. This is important and I want to reiterate what this means.
Whenever I talk about GLP-1s and their benefits, everybody wants to argue, well, wouldn't reducing your blood sugar, wouldn't optimizing your metabolic health, wouldn't weight loss already improve outcomes with X, Y, or Z? And yes, I would say yes. This showed that with other medications designed specifically to be cardioprotective and lower glucose, they did not see the dementia risk reduction.
So it's not as obvious as one would think it is. It's not just, oh, well, they lost weight, so of course their brain health improved. Or they lowered their blood sugar, so of course their brain health improved. Those things should indeed improve diabetes. brain health, but not like the GLP-1 did.
GLP-1 receptor agonists specifically were associated with a 45% relative reduction in dementia risk compared to controls. SGLT2 inhibitors showed no significant effect on dementia risk. Metformin had no eligible trials and the other drug, I cannot pronounce, pioglitazone showed no significant benefit.
Secondary findings, no statistically significant reduction in vascular dementia or Alzheimer's disease separately for any drug class. GLP-1 receptor agonist showed signals toward benefit across several cognitive measures, but no cognitive score improvements were consistently demonstrated across all included trials and no significant impact was seen on Lewy body dementia or frontotemporal dementia.
I get asked about that a lot, actually, about specific types of dementia. They had too few cases to really determine, so I'm not sure. The reason I got interested in GLP-1s, and for those who don't know what GLP-1 receptor agonists are, these are the drugs like Wegovy, Ozempic, Manjaro, Zepbound. These are all GLP-1 receptor agonists.
Showing 261–280 of 1,621 · page 14 of 82
← Previous
Next →